Overview
Wpd Pharmaceuticals is focused on developing biological and chemical molecules for targeted therapy aimed at treating brain glioma and other central nervous system cancers. The company is based in Warsaw, Poland.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2024-07-01. Active
07 1050 1298 1000 0090 8364 2224- 46 1050 1298 1000 0090 3303 8465
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jul 14, 2026 | Merger registered | |
| Mar 27, 2026 | Merger registered |
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
The following person or persons are authorized to represent the company and to make declarations on its behalf with respect to the company's property and non-property rights and obligations: in the case of a one-person management board – the President of the Management Board independently; in the case of a multi-member management board – two members of the management board acting jointly or a member of the management board acting jointly with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Michał Kojecki (58)  | Shareholder of a joint-stock company, 9.0%; Beneficjent rzeczywisty acrx investments limited, który posiada 1.102.647 akcji wpd pharmaceuticals s.a. (stanowiących 60,11% w kapitale zakładowym wpd pharmaceuticals s.a.), uprawniających do 1.102.647 głosów na walnym zgromadzeniu wpd pharmaceuticals s.a. (stanowiących 60,11% wszystkich głosów na walnym zgromadzeniu wpd pharmaceuticals s.a.) |
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
WPD Pharmaceuticalssp. z o.o. | 1,757,131.28 USD | 100% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| BioceltixS.A. | $616,315.97 | bioceltix.com | ||
| Green ZebrasS.A. | $328,658.91 | whygreenzebras.pl | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Oncotarget Wojciech JurczakS.K.A. | $192,291.27 | oncotarget.pl | ||
| WEA Techlabsp. z o.o. | $23,105.12 | weatechlab.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-04-29 | Share capital change (166,925.00 PLN → 183,425.00 PLN) | |
| 2025-08-21 | Share capital change (151,904.70 PLN → 166,925.00 PLN) | |
| 2025-01-23 | Share capital change (142,570.20 PLN → 151,904.70 PLN) | |
| 2024-09-02 | Share capital change (123,827.10 PLN → 142,570.20 PLN) | |
| 2024-07-12 | Share capital change (104,280.00 PLN → 123,827.10 PLN) |
FAQ
Last updated: 2026-06-15